Latest Updates
Read the latest news that impacts the oncology community.
- Published On: May 1st, 2024
An influential national advisory group has called for women to start getting mammograms beginning at age 40, but only every two years — a recommendation that highlights a rift within the cancer community
- Published On: April 30th, 2024
A New Jersey federal judge on Monday tossed cases brought by Johnson & Johnson and Bristol Myers Squibb against the Inflation Reduction Act, another victory for the law while Medicare works through the first year of price negotiations with industry
- Published On: April 30th, 2024
It was at 7 am, the time when the night team signs out to the day team, that the incoming residents heard the horrifying news: our electronic medical records (EMR) system (Epic) was down.
- Published On: April 30th, 2024
On April 23, 2024, the FTC voted 3-2 to adopt a final rule prohibiting non-compete agreements in employment contracts.
- Published On: April 30th, 2024
Last week was a big one in Washington for work-related news and policy.
- Published On: April 30th, 2024
A record number of drugs, including several used to treat life-threatening conditions, are in unprecedented short supply.
- Published On: April 30th, 2024
For community oncology practices, managing revenue is “probably the second most important thing that we do, after taking care of our patients,” says Glenn Balasky, executive director of Rocky Mountain Cancer Centers in Colorado.
- Published On: April 29th, 2024
The first legal challenges to the Federal Trade Commission's nationwide ban on noncompetes are flooding in from business groups claiming the commission overstepped its authority on Tuesday by approving the new regulation.
- Published On: April 29th, 2024
The Federal Trade Commission (FTC) voted to ban non-compete agreements after more than a year of debate. Now that the ruling has been made, what's next for employers — and the millions of employees who suddenly have a lot more professional freedom?
- Published On: April 29th, 2024
Hospitals in the 340B Drug Pricing Program that administer more high-cost drugs stand to benefit more from CMS’ plan to repay 340B hospitals a total of $9 billion in forgone reimbursements from 2018-2022, according to a new study.